Trial Profile
Assessment of Safety, Tolerability and Pharmacokinetics of Single Ascending Subcutaneous Doses of MOR107 in Healthy Male Subjects and Pharmacodynamics in Healthy Male Subjects on a Low Sodium Diet
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs MOR 107 (Primary)
- Indications Diabetic nephropathies; Fibrosis
- Focus Adverse reactions; First in man
- Sponsors Lanthio Pharma
- 06 Feb 2018 Status changed from recruiting to discontinued as part 1 was completed successfully and part 2 was not conducted.
- 03 Mar 2017 New trial record